Superpower peptides available for pre-order. Get first access.

Peptide science

What are the side effects of PTD-DBM?

No human trial of PTD-DBM is registered, so its side effects in people are unknown. See what animal data, Wnt risks, and online products show.

Quick answer

No human trial of PTD-DBM is registered on ClinicalTrials.gov, so its side-effect profile in people is unknown. Everything on record comes from cells and mice, including a 24-week mouse skin study that found no change in tumor development. The Wnt-pathway cancer concern is theoretical. Products sold online add their own risk, since tests of other peptides found purity as low as 5% and contamination with arsenic and lead.

Published
November 11, 2026
Last updated
November 11, 2026

What is known about PTD-DBM side effects and safety

The side effects of PTD-DBM in people are unknown, because no human trial of the peptide is registered1 or published. Tolerability, immune response, and absorption through skin remain open questions.

Human tolerability of PTD-DBM has never been measured in a published trial. PTD-DBM's record is hair regrowth in mice2 and experiments in cells, follicles, and mice3.

Immune response is the second open question. Peptide manufacturing impurities can introduce T-cell epitopes4, fragments that immune cells recognize as foreign. That risk is hardest to judge without clinical data5, and immunogenic profiling of hair peptides stays sparse6.

Absorption through skin is the third. The PTD in PTD-DBM is a protein transduction domain, a sequence built to carry cargo across cell membranes7. Sequences like it are studied for moving molecules through skin8, and how much of a topical dose reaches the bloodstream in people is unmeasured. PTD-DBM also raises collagen I in cultured human dermal fibroblasts9, the connective-tissue cells of skin, so its activity reaches beyond the follicle. PTD-DBM's boost to Wnt signaling raises a separate question about cancer.

Theoretical risks from the Wnt pathway

The cancer concern around PTD-DBM is theoretical and belongs to the pathway, not the peptide. Deregulated Wnt/beta-catenin signaling10, a pathway that steers how tissues develop and renew, is tied to serious disease, and aberrant activation contributes to tumor initiation and progression11.

The clearest examples come from skin. Mice engineered to carry a stabilized beta-catenin grew hair follicle tumors12, and at least 75% of human pilomatricomas13, a hair-matrix skin tumor, carry activating beta-catenin mutations.

Those are genetic models, a long way from a peptide that releases a brake. CXXC5, the protein PTD-DBM targets, acts across pathways beyond the hair follicle14. One long experiment applied topical PTD-DBM in a mouse skin-cancer model and found it did not alter tumor development over 24 weeks15. One species and one tumor type leave the human question open. The products a buyer can actually get add risks of another kind.

Risks from PTD-DBM bought from unregulated sellers

Much of the risk around PTD-DBM comes from where it is bought. Research-peptide sellers work outside manufacturing standards and with little safety monitoring behind them16, so identity, purity, and sterility rest on the seller's word.

Testing of other peptides from these channels turned up low purity and toxic contaminants. Screening of falsified peptide drugs found purity between 5% and 75%17 in cysteine-containing peptides, alongside arsenic and lead. Test purchases of a peptide drug sold online without a prescription measured 7.7% to 14.37% purity against the 99% claimed18. FDA names impurities and aggregation (peptide molecules clumping together) among the reasons a compounded peptide may present significant safety risks19. Neither purity study tested PTD-DBM. Both describe the market a buyer would be using. Some people carry more risk into that market than others.

Who should be most cautious about PTD-DBM

A few groups have the clearest reasons for caution around PTD-DBM, which has no approved indication, unlike the drugs it is most often compared with.

None of these is a contraindication in the regulatory sense, since PTD-DBM has no approved use.

Where can I learn about peptides?

Superpower’s peptide library separates what a peptide has shown in animals from what has been measured in people, so a compound like PTD-DBM is easy to place. Every guide is written and fact-checked by a team of health journalists and licensed clinicians.

Readers curious about how peptides cross membranes, or why the pathways they touch matter, can explore the science behind peptides.

IMPORTANT SAFETY INFORMATION

PTD-DBM is not approved by the FDA for any medical use. Research on this compound has been limited primarily to laboratory and animal studies, with little to no human clinical trial data available. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. PTD-DBM is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

No human clinical safety data exists for PTD-DBM. The complete side effect profile, systemic absorption characteristics, immunogenicity potential, and long-term safety in humans are unknown.

PTD-DBM should not be used by anyone outside an IRB-approved clinical research study; there is no approved indication and no contraindication table because there is no approved use. Populations of particular theoretical concern based on PTD-DBM's proposed mechanism include: active or prior cancer, particularly Wnt-pathway-driven tumors; a personal or family history of Wnt-driven tumors, such as familial adenomatous polyposis; pregnancy or breastfeeding (Wnt signaling plays critical roles in embryonic development); and known hypersensitivity to peptide products.

Warnings: unknown systemic absorption from topical application; theoretical proliferative risk via Wnt pathway disinhibition; no Phase 1 tolerability data in humans; protein transduction domain may increase dermal penetration and systemic exposure beyond that of conventional topical peptides.

Products sold online as PTD-DBM are unregulated and have not been tested for purity, identity, potency, or safety by any regulatory authority. Contamination, mislabeling, and dosing inaccuracies are documented risks of the unregulated research peptide market.

No FDA-approved prescribing information exists for PTD-DBM. For questions about hair loss evaluation and evidence-based options, consult a licensed dermatologist or healthcare provider.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to PTD-DBM. PTD-DBM is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science